General Information of Drug Combination (ID: DCO1DM0)

Drug Combination Name
Glycopyrrolate Neostigmine
Indication
Disease Entry Status REF
Gastrointestinal Dysfunction Phase 1 [1]
Component Drugs Glycopyrrolate   DM2M3ZA Neostigmine   DM6T2J3
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Glycopyrrolate
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [2]
Chronic obstructive pulmonary disease CA22 Approved [3]
Glycopyrrolate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Muscarinic acetylcholine receptor M1 (CHRM1) TTZ9SOR ACM1_HUMAN Antagonist [6]
------------------------------------------------------------------------------------
Glycopyrrolate Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Indication(s) of Neostigmine
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Approved [4]
Urinary retention MF50.3 Approved [5]
Neostigmine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Acetylcholinesterase (AChE) TT1RS9F ACES_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Neostigmine Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Neostigmine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Decreases Activity [10]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Affects Response To Substance [11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Airway Reflexes, Protective DCOIW4S N. A. Phase 4 [12]
Surgery DCNJP9A N. A. Phase 4 [13]
Anesthesia, General DC0I7J9 N. A. Phase 3 [14]
Anesthesia, General DCX75WN N. A. Phase 3 [14]
Surgical Procedures, Elective DCJMR2I N. A. Phase 1 [15]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02574611) Use of High Resolution Colonic Manometry in Studying Motility
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7459).
3 Clinical pipeline report, company report or official report of Novartis.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Neostigmine FDA Label
6 Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701.
7 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
8 Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
9 Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109.
10 Hairy-root organ cultures for the production of human acetylcholinesterase. BMC Biotechnol. 2008 Dec 23;8:95.
11 Fresh frozen plasma transfusion for reversal of prolonged post-anaesthesia apnoea. Transfus Med. 2008 Apr;18(2):134-6. doi: 10.1111/j.1365-3148.2008.00851.x.
12 ClinicalTrials.gov (NCT01199237) Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block
13 ClinicalTrials.gov (NCT03939923) Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
14 ClinicalTrials.gov (NCT00473694) Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
15 ClinicalTrials.gov (NCT01479764) Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)